- Home
- GSL vs SNY Comparison
GSL vs SNY Comparison
Compare GSL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- SNY
- Stock Information
- Founded
- GSL 2007
- SNY 1994
- Country
- GSL Greece
- SNY France
- Employees
- GSL N/A
- SNY N/A
- Industry
- GSL Marine Transportation
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- SNY Health Care
- Exchange
- GSL Nasdaq
- SNY Nasdaq
- Market Cap
- GSL 758.7M
- SNY 123.6B
- IPO Year
- GSL 2006
- SNY N/A
- Fundamental
- Price
- GSL $21.99
- SNY $50.25
- Analyst Decision
- GSL Strong Buy
- SNY Buy
- Analyst Count
- GSL 1
- SNY 2
- Target Price
- GSL $29.00
- SNY $62.50
- AVG Volume (30 Days)
- GSL 280.7K
- SNY 3.1M
- Earning Date
- GSL 05-19-2025
- SNY 04-24-2025
- Dividend Yield
- GSL 8.20%
- SNY 3.09%
- EPS Growth
- GSL 17.78
- SNY 39.56
- EPS
- GSL 9.67
- SNY 5.45
- Revenue
- GSL $705,529,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- GSL $1.84
- SNY $5.35
- Revenue Next Year
- GSL N/A
- SNY $6.69
- P/E Ratio
- GSL $2.22
- SNY $9.56
- Revenue Growth
- GSL 5.82
- SNY N/A
- 52 Week Low
- GSL $17.73
- SNY $45.80
- 52 Week High
- GSL $30.32
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- GSL 57.54
- SNY 39.23
- Support Level
- GSL $21.26
- SNY $51.67
- Resistance Level
- GSL $22.23
- SNY $55.73
- Average True Range (ATR)
- GSL 0.47
- SNY 0.88
- MACD
- GSL 0.18
- SNY -0.09
- Stochastic Oscillator
- GSL 92.28
- SNY 7.84
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.